About this trial

Eligible patients will be interviewed by research staff to explain the trial design and rationale. Written informed consent will be obtained from patients who voluntarily agree to participate. Demographics and medical history will be obtained. A 12-lead ECG will be performed; it has not been performed within 6 months. A photo of the 12-lead ECG will be taken by research staff using the DigitHeart-2 smartphone application. Predictions from DigitHeart-2/MERL-ECHO and other machine learning models hosted by the investigator team for each of the target anatomical and mechanical properties will be recorded. The cardiologist in charge of the patient, who is blinded to the prediction results from DigitHeart-2/MERL-ECHO, will perform echocardiography according to American Society of Echocardiography guidelines, which will serve as the gold standard for accuracy evaluation.

Eligibility criteria

Qualifiers

aged ≥ 18 years old

planned to have echocardiography performed

voluntarily agree to participate in the trial.

Disqualifiers

had echocardiography performed within 1 month

pacemaker rhythm on ECG

dextrocardia

complex adult congenital heart disease

Trial design

Treatments tested in this trial

  • echocardiography

Treatment groups

478 Participants
are divided into 1 treatment group

Locations

1
Department of Medicine Queen Marry Hospital, Hong Kong Hong Kong Hong Kong

Sponsors and collaborators

The University of Hong Kong

Lead sponsor